CLINICAL ANALYSES OF FACTORS INFLUENCING L‐DOPA TREATMENT OF PARKINSON'S SYNDROME
Authors:
- 12 January 1972
- journal article
- clinical trial
- Published by Wiley in Acta Medica Scandinavica
- Vol. 192 (1-6) , 1-11
Abstract
One hundred and twenty‐three patients with Parkinson's disease have been treated with L‐dopa for 6–31 months. Rigidity was improved in 85%, hypokinesia in 93%, tremor in 69%, speech disturbances in 30% and mental depression in 48% of the patients. The existence of any correlations between measured variables was tested in 260 tests. The L‐dopa dosage was higher in men than in women. Improvement in ADL disability was inversely correlated to age. This improvement was directly correlated to the occurrence of tremor before treatment and to the appearance of involuntary movements during treatment. There was a correlation between the appearance of involuntary movements and the appearance of muscular hypotonia. These and other observations allowed conclusions concerning the proper indications for L‐dopa treatment of Parkinson's syndrome.Keywords
This publication has 15 references indexed in Scilit:
- ORALL‐DOPA TREATMENT OF PARKINSONISMActa Medica Scandinavica, 1970
- Modification of Parkinsonism — Chronic Treatment with L-DopaNew England Journal of Medicine, 1969
- Dopa and ParkinsonismBMJ, 1967
- Aromatic Amino Acids and Modification of ParkinsonismNew England Journal of Medicine, 1967
- Demonstration and mapping out of nigro-neostriatal dopamine neuronsLife Sciences, 1964
- Der L-Dioxyphenylalanin (=L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: Zur Pathogenese und Behandlung der Parkinson-AkineseEuropean Archives of Psychiatry and Clinical Neuroscience, 1962
- Dopamine and Basal Ganglia DiseasesArchives of Neurology, 1961
- Occurrence and distribution of dopamine in brain and other tissuesCellular and Molecular Life Sciences, 1959
- 3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine AntagonistsNature, 1957
- Some Methods for Strengthening the Common χ 2 TestsBiometrics, 1954